ClinicalTrials.gg
CompletedNCT05115110MANATEEUpdated Nov 4, 2026

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

A Phase 2/3 interventional study of RO7204239 and Placebo in Spinal Muscular Atrophy (SMA), sponsored by Hoffmann-La Roche. Completed at 29 sites in 12 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment

Updated Nov 4, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
2 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche — 1 open to participants now, 4 under way, none of them phase 3. Muscular Atrophy, Spinal · Hoffmann-La Roche.

Enrollment
6th of 15
97 · median 35
Started
2022
with 1 other
Phase 2/3
Only one
of the 18
Registered
13th of 18
by date

Among the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 2/3, and was the 13th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

1 of the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, or all of them as a file.
02

Study summary

Risdiplam works by helping the body produce more survival motor neuron (SMN) protein throughout the body. This means fewer motor neurons - nerve cells that pass impulses from nerves to muscles to cause movement - are lost, which may improve how well muscles work in people with SMA. RO7204239 is an investigational anti-myostatin antibody that is designed to target myostatin. Myostatin plays an important role in the regulation of skeletal muscle size by controlling growth. Inhibiting myostatin may help muscles grow in size and strength. RO7204239 in combination with risdiplam, which is designed to increase the amount of SMN protein throughout the body, has the potential to further improve motor function and clinical outcomes for people living with SMA.

This trial will study the safety and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy (SMA). The trial has two parts; Part 1 is the dose-finding part in SMA patients that are either ambulant (aged 2-10 years) or non-ambulant (aged 5-10 years) within separate cohorts, and Part 2 is the pivotal part in SMA patients aged 2-25 years that are ambulant.

03

Conditions studied

  • Spinal Muscular Atrophy (SMA)
04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age at screening: Part 1 Cohorts A (ambulant participants), B (ambulant participants), and D (non-ambulant participants): 5-10 years, inclusive; Part 1 Cohort C (ambulant participants): 2-4 years, inclusive; Part 2 (ambulant participants): 2-25 years, inclusive
  • Participants who have a confirmed genetic diagnosis of 5q-autosomal recessive SMA
  • Symptomatic SMA disease, as per investigator's clinical judgement
  • Participants who have received previous SMA disease-modifying therapies may be included provided that: Onasemnogene abeparvovec was received at least 90 days prior to screening. Participants should be tapered off prior to receiving risdiplam. In addition, participants should have normal levels of liver function tests, coagulatory parameters, , and troponin-I at 90 days after administration of onasemnogene abeparvovec or at least 1 month after tapering off corticosteroids, whichever comes later; Nusinersen last dose was received at least 90 days prior to screening; Risdiplam is switched to the medicinal product (IMP) provided by the site

Inclusion Criteria for Part 1 Cohorts A, B, and C and Part 2 only:

  • Participants who are ambulant, where ambulant is defined as able to walk/run unassisted (i.e., without the use of assistive devices such as canes, walking sticks, crutches, walkers, person/hand-held assistance, braces, orthoses, over the malleoli insoles or any other type of support) 10 meters in ≤ 30 seconds as measures by the Timed 10-Meter Walk/Run Test [10MWRT] at screening

Inclusion Criteria for Part 1 Cohort D only:

  • Participants who are able to sit, defined by: A score of 3 on Item 9 of the MFM32 (sitting without upper limb support while maintaining contact between the two hands for 5 seconds); A score of at least 2 on Item 10 of the MFM32 (while seated, leaning forward to touch a tennis ball and sitting back again, either with or without upper limb support)
  • Participants who are able to raise a standardized plastic cup with a 200g weight in it to the mouth, using both hands if necessary, defined by a score of 3 on the entry item of the Revised Upper Limb Module (RULM)

Exclusion Criteria:

  • Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening or 5 half-lives of the drug whichever is longer, with the exception of those who have completed a risdiplam study, or participated in a nusinersen or onasemnogene abeparvovec study
  • Receiving or have received previous administration of anti-myostatin therapies
  • Any history of cell therapy
  • Hospitalization for a pulmonary event within the last 2 months or planned hospitalization at the time of screening
  • Past surgery for scoliosis or hip fixation in the 6 months preceding screening or planned within the next 9 months (Part 1) or 21 months (Part 2)
  • Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system diseases considered to be
  • Clinically significant abnormalities at screening from average of triplicate measurement, abnormal findings at echocardiography, or cardiovascular disease indicating a safety risk for participants at the time of screening
  • Any major illness within 1 month before screening
  • Received any multidrug and toxin extrusion (MATE1/2K) substrates within 2 weeks before screening
  • Hereditary fructose intolerance
  • Used any of the following medications within 90 days prior to screening: riluzole, valproic acid, hydroxyurea, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic steroids, probenecid, acetyl cholinesterase inhibitors, agents that could potentially increase or decrease muscle strength, and agents with known or presumed histone deacetylase (HDAC) inhibitory effect
  • Clinically significant abnormalities in laboratory test results at the time of screening
  • Ascertained or presumptive to RO7204239 or risdiplam, or to the constituents of its formulations
  • Clinically relevant history of anaphylactic reaction requiring inotropic support
  • Any abnormal skin conditions, pigmentation or lesions in the area intended for SC injection (abdomen) and that would prevent visualization of potential injection site reactions to RO7204239
  • Immobilization, surgical procedures, fracture, or trauma to the upper or lower limbs within 90 days prior to screening

Exclusion Criteria for Part 1 Cohorts A and B only:

  • Participants with for MRI scan (including, but not restricted to, claustrophobia, pacemaker, artificial heart valves, cochlear implants, presence of foreign metal objects in heart or body, including spinal rods, intracranial vascular clips, insulin pumps, etc.), difficulties maintaining a prolonged supine position, or any other clinical history or examination finding that would pose a potential hazard in combination with MRI

Exclusion Criteria for Part 1 Cohort D only:

  • Participants who are unable to adopt the correct position to endure adequate quality of DXA scan acquisition, as determined by the DXA scan technologist
  • Participants who have contractures at screening that would interfere with DXA scan acquisition or functional assessments, as confirmed by the DXA scan technologist and clinical evaluator
  • For participants able to take steps only: Able to walk unassisted (i.e., without the use of assistive devices such as canes, walking sticks, crutches, walkers, person/hand held assistance, braces, orthoses, over the malleoli insoles or any other type of support) 10 meters in ≤ 30 seconds as measured by the timed 10MWRT at screening
  • Participants who have severe scoliosis (curvature > 40°) at screening based on the participant's most recent X-ray as performed per standard of care or scoliosis that would interfere with functional assessments, as confirmed by the clinical evaluator. An X-ray is not required if it is not clinically indicated (e.g., in participants with mild scoliosis)
  • Participants who require invasive ventilation, tracheostomy, or the use of noninvasive ventilation (e.g., bilevel positive airway pressure) during the daytime
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    RO7204239 + Risdiplam

    Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization. Participants enrolled in Part 1 will receive RO7204239 (low or high dose) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks. Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with RO7204239 + risdiplam for 72 weeks. Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years.

    Drug: RO7204239 · Drug: Risdiplam

  • Active comparator
    Placebo + Risdiplam

    Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization. Participants enrolled in Part 1 will receive placebo (low or high dose-matched) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks. Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with placebo + risdiplam for 72 weeks. Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years.

    Drug: Placebo · Drug: Risdiplam

Interventions

  • RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen. RO7204239 will be investigated at low- and high-dose in Part 1.

  • DrugPlacebo

    Placebo will be administered Q4W by SC injection into the abdomen.

  • Risdiplam will be administered orally once daily (QD) for the duration of the study.

    Also known as: RO7034067, Evrysdi

06

What researchers measure

Primary outcomes

  1. Part 1 - Percentage of participants with adverse events (AEs)

    Time frame: Up to 4.5 years

  2. Part 1 - Incidence of relevant echocardiographic parameter z scores > 2

    Time frame: Up to 4.5 years

  3. Part 1 - Serum concentration of RO7204239

    Time frame: Through Week 96

  4. Part 1 - Time to maximum serum concentration (Cmax) of RO7204239

    Time frame: Through Week 96

  5. Part 1 - Area under the curve (AUC) of RO7204239

    Time frame: Through Week 96

  6. Part 1 - Trough concentration (Ctrough) of RO7204239

    Time frame: Through Week 96

  7. Part 1 - Plasma concentration of risdiplam

    Time frame: Week 21

  8. Part 1 - Plasma concentration of risdiplam metabolite (M1)

    Time frame: Week 21

  9. Part 1 - Cmax of risdiplam

    Time frame: Week 21

  10. Part 1 - AUC of risdiplam

    Time frame: Week 21

  11. Part 1 - Ctrough of risdiplam

    Time frame: Week 21

  12. Part 1 - Incidence of anti-drug antibodies (ADAs)

    Time frame: Through Week 96

  13. Part 1 - Change from baseline in serum concentration of total myostatin

    Time frame: Through Week 85

  14. Part 1 - Change from baseline in serum concentration of free latent myostatin

    Time frame: Through Week 85

  15. Part 1 - Change from baseline in serum concentration of mature myostatin

    Time frame: Through Week 85

  16. Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant thigh muscles as assessed by magnetic resonance imaging (MRI) in participants aged at least 5 years

    Time frame: Week 24 of combination treatment

  17. Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant calf muscles as assessed by MRI in participants aged at least 5 years

    Time frame: Week 24 of combination treatment

  18. Part 2 - Change from baseline in Revised Hammersmith Scale (RHS) total score

    Time frame: Week 72 of combination treatment (study Week 80)

Secondary outcomes

  1. Part 2 - Change from baseline in Motor Function Measure (MFM) Domain 1 + Domain 2 (D1 + D2) score

    Time frame: Week 72 of combination treatment (study Week 80)

  2. Part 2 - Change from baseline in MFM-32 total score

    Time frame: Week 72 of combination treatment (study Week 80)

  3. Part 2 - Change from baseline in time taken to rise from the floor as measured by RHS Item 25

    Time frame: Week 72 of combination treatment (study Week 80)

  4. Part 2 - Change from baseline in time taken to walk/run 10 meters as measured by RHS Item 19

    Time frame: Week 72 of combination treatment (study Week 80)

  5. Part 2 - Percent change from baseline in lean mass as assessed by full body dual energy X-ray absorptiometry (DXA) scan in participants aged at least 5 years

    Time frame: Week 72 of combination treatment (study Week 80)

  6. Part 2 - Percentage of participants with adverse events (AEs)

    Time frame: Up to 4.5 years

  7. Part 2 - Serum concentration of RO7204239

    Time frame: Through Week 80

  8. Part 2 - Cmax of RO7204239

    Time frame: Through Week 80

  9. Part 2 - AUC of RO7204239

    Time frame: Through Week 80

  10. Part 2 - Ctrough of RO7204239

    Time frame: Through Week 80

  11. Part 2 - Plasma concentration of risdiplam

    Time frame: Week 32

  12. Part 2 - Plasma concentration of risdiplam metabolite (M1)

    Time frame: Week 32

  13. Part 2 - Cmax of risdiplam

    Time frame: Week 32

  14. Part 2 - AUC of risdiplam

    Time frame: Week 32

  15. Part 2 - Ctrough of risdiplam

    Time frame: Week 32

  16. Part 2 - Incidence of ADAs

    Time frame: Through Week 80

07

Study locations

29 sites
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Sydney Children's Hospital
    Randwick, New South Wales 2031, Australia
  • UZ Gent
    Ghent, 9000, Belgium
  • Chr de La Citadelle
    Liège, 4000, Belgium
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3N1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • McGill University Health Centre - Glen Site
    Montreal, Quebec H4A 3J1, Canada
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Policlinico Agostino Gemelli
    Rome, Lazio 00168, Italy
  • Fondazione IRCCS Istituto Neurologico ?Carlo Besta?
    Milan, Lombardy 20133, Italy
  • Asst Grande Ospedale Metropolitano Niguarda
    Milan, Lombardy 20162, Italy
  • Ospedali Riuniti Torrette di Ancona
    Ancona, The Marches 60126, Italy
  • Kobe University Hospital
    Hyōgo, 650-0017, Japan
  • Kagoshima University Hospital
    Kagoshima, 890-8520, Japan
  • National Center for Global Health and Medicine
    Shinjuku-ku, 162-8655, Japan
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Instytut Centrum Zdrowia Matki Polki
    ?ód?, 93-338, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gda?sk, 80-952, Poland
  • Uniwersytecki Szpital Kliniczny w Poznaniu
    Późna, 60-355, Poland
  • Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
    Warsaw, 02-097, Poland
  • Instytut Pomnik Centrum Zdrowia Dziecka
    Warsaw, 04-730, Poland
  • CHULC, E.P.E. - Hospital Dona Estefania
    Lisbon, 1169-045, Portugal
  • Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
  • Hospital Sant Joan De Deu
    Esplugues de Llobregas, Barcelona 08950, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario la Fe
    Valencia, 46026, Spain
  • Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2022 to primary completion in Nov 2026, 53 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2021
First posted
Nov 10, 2021
StartActual
Jun 2, 2022
Primary completionActual
Nov 2, 2026was Oct 2026
CompletionActual
Nov 2, 2026was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Sites
1 site removed
Show 1 removed
  • IRCCS Istituto Giannina Gaslini · Genoa, Italy
Nov 4, 2026
Primary completion
Oct 28, 2026→Nov 2, 2026 (actual)
Nov 4, 2026
Study completion
Oct 28, 2026→Nov 2, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    1 site removed
    Show 1 removed
    • IRCCS Istituto Giannina Gaslini · Genoa, Italy
    Primary completion Oct 28, 2026→Nov 2, 2026 (now actual)
    Study completion Oct 28, 2026→Nov 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05115110
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Jun 2, 2022
Primary completion
Nov 2, 2026
Completion
Nov 2, 2026
Last update
Nov 4, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emugrobart

Start the discussion